The National Institute of General Medical Sciences (NIGMS) awarded Pearl Bio, Inc. a $549,384 Project Grant (R43GM150368) under the Biomedical Research and Research Training program (CFDA 93.859) to develop next-generation protein biologics programmed with multifunctional synthetic chemistries. The grant aims to address major barriers in the advancement and clinical use of cytokine protein therapeutics, such as systemic immune activation and rapid proteolytic degradation. Through this funding, Pearl Bio will leverage its synthetic biology and genomically recoded organism capabilities to create novel biological materials with improved therapeutic efficacy and biomedical applications. The project has an anticipated completion date of August 31, 2025.
Generated 1/28/25, 7:09 AM